Ocular ’ s Dextenza meets primary endpoints in Phase III trial

Shares in Ocular Therapeutix (NSDQ:OCUL) rose more than 5% today after the company said its Dextenza post-surgical ocular pain relief implant met primary endpoints in the company’s most recent Phase III trial. The hydrogel plug, inserted into a patient’s tear duct, is designed to deliver a sustained dose of dexamethasone over 4 weeks following ophthalmic surgery. The FDA is slated to make a decision whether or not to approve Dextenza for the treatment of ocular pain after ophthalmic surgery by July 19, 2017. Get the full story at our sister site, Drug Delivery Business News. The post Ocular’s Dextenza meets primary endpoints in Phase III trial appeared first on MassDevice.
Source: Mass Device - Category: Medical Equipment Authors: Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Wall Street Beat Ocular Therapeutix Source Type: news